Literature DB >> 19200978

Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.

Maria A Manzanares1, Jose Lui Gómez-Palomares, Elisabetta Ricciarelli, Eleuterio R Hernández.   

Abstract

OBJECTIVE: To determine whether inducing ovulation with a GnRH agonist in patients with polycystic ovaries (PCO) would permit oocyte retrieval without the burden or risk of cancellation, coasting, or ovarian hyperstimulation syndrome (OHSS), thus maintaining pregnancy rates by allowing embryo cryopreservation for transfer in a subsequent cycle.
DESIGN: Retrospective observational study.
SETTING: Private institution. PATIENT(S): Forty-two women who had previously experienced a controlled ovarian hyperstimulation (COH)/IVF cycle that had to be cancelled because of an elevated risk of OHSS. INTERVENTION(S): Forty-two PCO patients with a previous cancelled IVF cycle were assigned to a second controlled ovarian stimulation with recombinant FSH (75-150 IU/day) + GnRH antagonist (0.25 mg/day). Embryos were cryopreserved and transferred in a later cycle. MAIN OUTCOME MEASURE(S): OHSS, oocyte retrieval, and pregnancy rates. RESULT(S): In the first COH, the cycle had to be cancelled to avoid OHSS because E(2) serum levels were above safety levels (4809.6 +/- 2947.7). However, in the second cycle (ovulation triggered with a GnRH agonist) and independent of E(2) serum levels (4518.5 +/- 2118.85), all PCO patients eventually completed oocyte retrieval and frozen ET. With regard to pregnancy rates, 33% of patients receiving a transfer of a previously frozen embryo were successful. No patient developed OHSS. CONCLUSION(S): Triggering ovulation with a GnRH agonist followed by embryo cryopreservation allows PCO patients to complete a COH/IVF cycle with no cycle cancellation, coasting, or OHSS and, finally, to attain good pregnancy rates. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200978     DOI: 10.1016/j.fertnstert.2008.12.019

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  A new treatment to avoid severe ovarian hyperstimulation utilizing insights from in vitro maturation therapy.

Authors:  B I Rose
Journal:  J Assist Reprod Genet       Date:  2013-12-01       Impact factor: 3.412

Review 3.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

4.  Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Anuja Dokras
Journal:  Fertil Steril       Date:  2014-11-06       Impact factor: 7.329

5.  Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.

Authors:  Yu-Hung Lin; Mei-Zen Huang; Jiann-Loung Hwang; Heng-Ju Chen; Bih-Chwen Hsieh; Lee-Wen Huang; Chii-Ruey Tzeng; Kok-Min Seow
Journal:  J Assist Reprod Genet       Date:  2013-04-20       Impact factor: 3.412

6.  Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.

Authors:  Deepika Krishna; Snehal Dhoble; Gautham Praneesh; Suvarna Rathore; Amit Upadhaya; Kamini Rao
Journal:  J Hum Reprod Sci       Date:  2016 Jul-Sep

Review 7.  GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis.

Authors:  Thor Haahr; Matheus Roque; Sandro C Esteves; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-07       Impact factor: 5.555

8.  A modified GnRH antagonist method in combination with letrozole, cabergoline, and GnRH antagonist for PCOS: Safe and effective ovarian stimulation to treat PCOS and prevent OHSS.

Authors:  Yasuho Yanagihara; Atsushi Tanaka; Motoi Nagayoshi; Izumi Tanaka; Rina Shinohara; Fumihisa Fukushima; Akihiro Tanaka; Motoharu Ohno; Takashi Yamaguchi; Atsuo Itakura
Journal:  Reprod Med Biol       Date:  2021-11-25

9.  Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.

Authors:  Georg Griesinger; Pierre J M Verweij; Davis Gates; Paul Devroey; Keith Gordon; Barbara J Stegmann; Basil C Tarlatzis
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

10.  The deferred embryo transfer strategy improves cumulative pregnancy rates in endometriosis-related infertility: A retrospective matched cohort study.

Authors:  Mathilde Bourdon; Pietro Santulli; Chloé Maignien; Vanessa Gayet; Khaled Pocate-Cheriet; Louis Marcellin; Charles Chapron
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.